Sugi Predict

Sugi Predict / Compounds / SCHEMBL650259

SCHEMBL650259

SCHEMBL650259

COc1ccc(-c2c[nH]c(-c3ccccc3)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.51
▸ RAB9A P51151 6/20 0.51
▸ SCN2A Q99250 1/20 0.51
▸ KDM4E B2RXH2 6/20 0.50
▸ ALDH1A1 P00352 5/20 0.50
▸ LMNA P02545 2/20 0.50
▸ ACACA Q13085 1/20 0.50
▸ ENPP3 O14638 1/20 0.50
▸ ENPP1 P22413 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ DYRK1A Q13627 1/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ PKM P14618 1/20 0.49
▸ TP53 P04637 3/20 0.48
▸ MAPT P10636 3/20 0.48
▸ MAPK13 O15264 1/20 0.48
▸ RAF1 P04049 1/20 0.48
▸ MAPK12 P53778 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7142078 1.00 NPC1 (0.51) NPC1RAB9ASCN2AKDM4EALDH1A1
SCHEMBL11771726 0.93 KDM4E (0.50) NPC1RAB9AKDM4EALDH1A1LMNA
SCHEMBL8110189 0.89 ADORA2A (0.49) NPC1RAB9ASCN2AKDM4EALDH1A1
SCHEMBL17279819 0.89 NPC1 (0.50) NPC1RAB9AKDM4EALDH1A1LMNA
SCHEMBL17280156 0.86 MAPK13 (0.48) NPC1RAB9AKDM4EALDH1A1NPSR1
SCHEMBL7146244 0.86 NR1H2 (0.58) NPC1RAB9AKDM4EALDH1A1NPSR1
SCHEMBL7135272 0.86 PDGFRB (0.47) NPC1RAB9AKDM4EALDH1A1TDP1
SCHEMBL26464666 0.86 MCL1 (0.47) NPC1RAB9AKDM4EALDH1A1TDP1
SCHEMBL26464174 0.86 PDGFRB (0.47) NPC1RAB9AKDM4EALDH1A1TDP1
Hydrochloric Acid SCHEMBL7140665 0.84 MAPK13 (0.48) NPC1RAB9AKDM4EALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 — — US claimed
CN-1265033-A Certain diarylimidaozle derivatives, new class of NPY speific ligands NEUROGEN CORP (US) 2000-08-30 — — CN claimed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 — — EP claimed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 — — WO claimed
US-8846948-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-30 — — US disclosed
WO-2013087738-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 — — WO disclosed
US-20130150355-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-13 — — US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 — — US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 — — US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 — — US disclosed
CN-101665463-B Benzobisimidazole compound, synthesis method and application NANJING UNIVERSITY OF TECHNOLOGY 2012-01-04 — — CN disclosed
CN-101665463-A Benzobisimidazole compound, synthesis method and application NANJING UNIVERSITY OF TECHNOLOGY 2010-03-10 — — CN disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 — — US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 — — US disclosed
EP-1490343-A1 NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS Neurogen Corporation (US) 2004-12-29 — — EP disclosed
US-20040116424-A1 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION 2004-06-17 — — US disclosed
WO-2003082829-A1 NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2003-10-09 — — WO disclosed
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 — — US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 — — US disclosed
CN-1265033-A Certain diarylimidaozle derivatives, new class of NPY speific ligands NEUROGEN CORP (US) 2000-08-30 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150355-A1 NOVEL COMPOUNDS GRM5, GRIN2A, GRIN1 NPC1 1807/4885RAB9A 669/4885SCN2A 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.